Don't live life without it in your portfolio ;-0
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Etsy shares soar more than 24% after raising full-year revenue guidanceEtsy stock soared more than 24.8 percent Wednesday as the company raised its annual revenue forecast and beat on quarterly earnings Tuesday.
Source: CNBC - 🏆 12. / 72 Read more »
Home Depot beats on comp sales, raises its full-year forecastsHome Depot's third-quarter comparable-store sales jumped 5.4%, beating estimates. The retailer raised its full-year earnings and revenue forecasts.
Source: BusinessInsider - 🏆 729. / 51 Read more »
Boeing beats and raises its full-year profit forecastBoeing beat on both the top and bottom lines and raised its full-year profit forecast. Shares gained more than 4%.
Source: BusinessInsider - 🏆 729. / 51 Read more »
Endo stock rises 6% after Q3 beats and upbeat 2018 guidanceEndo International PLC shares rose 6% in Thursday premarket trade after the company reported third-quarter adjusted profit and revenue beats and upbeat 2018 guidance. The company reported a net loss of $173.2 million, or a loss of 77 cents per share, after a loss of $96.7 million, or a loss of 43 cents per share in the year-earlier period. Endo said its adjusted earnings-per-share from continuing operations were 71 cents, above the FactSet consensus of 59 cents. Revenue declined to $745.5 million from $786.9 million in the year-earlier period, above the FactSet consensus of $694.9 million. The latest results reflect Endo's voluntary market withdrawal of the opioid pain medication Opana ER (notably, at the Food and Drug Administration's request), the company said, along with other factors like competitive pressures and discontinuations of U.S. generic drugs. Growth in the quarter, meanwhile, came from the company's launch of the antibiotic ertapenem for injection, an authorized generic for the brand-name of the antibiotic, Merck's Invanz, and continued growth in its U.S. brand-name sterile injectables products. Endo now expects 2018 revenue of $2.87 billion to $2.92 billion, above the FactSet consensus of $2.81 billion, and adjusted EPS from continuing operations of between $2.65 and $2.75, above the FactSet consensus of $2.60. Company shares have declined 1.2% over the last three months, compared with a 1.5% decline in the S&P 500 and a 2.3% rise in the Dow Jones Industrial Average . Endo?
Source: MarketWatch - 🏆 3. / 97 Read more »
Nokia earnings in line with expectations, confirms full-year guidanceTelecom network equipment maker Nokia reported quarterly earnings in line with market expectations Thursday. Is Nokia still alive? I thought it became another dinosaur!! Didn't know that this company was still in existence! I’ve seen a Nokia TV once. It was beautiful.
Source: CNBC - 🏆 12. / 72 Read more »
3M tanks after slashing full-year guidance3M plunged more than 7% ahead of Tuesday's opening bell after the company missed earnings estimate and cut its full-year guidance.
Source: BusinessInsider - 🏆 729. / 51 Read more »
LabCorp shares slide 4% premarket after company lowers full-year guidance
Source: MarketWatch - 🏆 3. / 97 Read more »
Eli Lilly beats earnings expectations, raises guidance
Source: MarketWatch - 🏆 3. / 97 Read more »
Walmart beats on earnings and raises guidance as online sales soarWalmart on Thursday reported better-than-expected profits and raised full-year guidance, sending shares up 1.42% before the opening bell.
Source: BusinessInsider - 🏆 729. / 51 Read more »
Starbucks Beats Earnings And Raises GuidanceIt was also encouraging to see the company raise guidance for fiscal 2019 earnings. The raised guidance to $2.68 to $2.73 per share which is higher than previous guidance of $2.61 to $2.66 per share.
Source: Forbes - 🏆 394. / 53 Read more »